Weight Loss
Tirzepatide (Dual GIP/GLP-1 Receptor Agonist)
Dual-action GIP/GLP-1 agonist — next-generation metabolic research compound
Select Size
Most researchers order 2+ vials per protocol
For research use only. Not for human consumption.
Overview
Tirzepatide is a first-in-class synthetic dual agonist targeting both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its 39-amino acid peptide structure incorporates a C-20 fatty diacid moiety for extended half-life via albumin binding. The dual-receptor mechanism engages complementary metabolic signaling pathways, making Tirzepatide a valuable tool for studying incretin biology, energy homeostasis, and lipid metabolism.
Specifications
| Form | Lyophilized Powder |
| Purity | ≥99% (HPLC Verified) |
| Storage | -20°C (Freeze Dried) |
| Molecular Weight | 4813.45 g/mol |
Frequently Asked Questions
Tirzepatide is a first-in-class synthetic dual agonist that targets both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its 39-amino acid structure includes a C-20 fatty diacid moiety for extended half-life via albumin binding.
While Semaglutide is a selective GLP-1 receptor agonist, Tirzepatide engages both GIP and GLP-1 receptors simultaneously. This dual-receptor mechanism activates complementary metabolic signaling pathways, making it a distinct tool for studying incretin biology and energy homeostasis.
All Tirzepatide batches are verified at ≥99% purity through third-party HPLC testing. Full Certificate of Analysis including mass spectrometry confirmation is included with every shipment.
Store the lyophilized powder at -20°C. After reconstitution with bacteriostatic water, keep refrigerated at 2–8°C and use within 28 days.
Also Available In These Kits
Complete Your Stack
Frequently purchased together with Tirzepatide
